MCL1 and cancer: Though changes in the corresponding protein expression levels of BAX, BCL-2, BIRC-5, and MCL1 need to be verified, their modulation by PEL and EPI, together with other published data on the reduction in cell viability of PEL and EPI, coupled with anti-inflammatory activities [17,18,19], disclose the potential protective properties for these compounds against cancer, and their role as candidate compounds for further preclinical studies.